In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Evolution of arrhythmic profile in patients with severe heart failure after cardiac resynchronization therapy.

Session Poster session 1

Speaker Eftihia Simeonidou

Event : EHRA 2017

  • Topic : arrhythmias and device therapy
  • Sub-topic : Cardiac Resynchronization Therapy
  • Session type : Poster Session

Authors : E Simeonidou (Athens,GR), C Pantsios (Athens,GR), G Giannakakis (Athens,GR), J Lekakis (Athens,GR)

Authors:
E Simeonidou1 , C Pantsios1 , G Giannakakis1 , J Lekakis1 , 12nd University Cardiology Dept, Attikon Hospital - Athens - Greece ,

Citation:
Europace ( 2017 ) 19 ( Supplement 3 ), iii99

Purpose: Although cardiac resynchronization therapy (CRT) is expected to reduce the risk of arrhythmias in heart failure patients (pts) by the induction of reverse remodeling, its real impact in severe arrhythmias is not clear. Aim of the study was to analyze the arrhythmias ensuing in pts receiving CRT therapy combined with ICD (CRTD).

Methods: The study population consisted of 66 severe heart failure pts with CRTD, (9 ? and 57?), mean age 61±14 years, with underlying disease ischemic cardiomyopathy in 34 and dilated cardiomyopathy in 32. Forty six pts received CRTD as primary prevention (group A) and 20 pts as secondary prevention (group B). Eight pts had permanent atrial fibrillation (AF) and 13 pts sustained at least one episode of PAF before device implantation. We analyzed the occurrence of ventricular tachycardia including appropriate VT therapies and atrial fibrillation as well.

Results: Forty eight pts were clinical responders, 8 super responders and 10 pts poor responders. After 10 years follow-up including at least one device replacement, we found almost similar incidence of sustained ventricular tachycardia (VT) (15%) and AF (25%) in both groups, irrelevant to clinical improvement and underlying substrate. Seven patients died of pump failure. Pts who received CRTD as secondary prevention, although good responders, continued to experience VT and appropriate therapies. In all groups development of electrical storm and resistant fast AF was a harbinger of heart failure deterioration.

Conclusion: Due to electrical and mechanical heterogeneity among severe heart failure pts the antiarrhythmic effect of CRTD is unpredictable. The arrhythmia risk in CRT pts is independent to CRT-induced improvement of the failing heart and irrelevant to heart failure origin.

This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are